布地奈德
差向异构体
代谢物
新陈代谢
化学
阿尔法(金融)
药理学
生物化学
立体化学
生物
内分泌学
皮质类固醇
医学
结构效度
护理部
患者满意度
作者
Staffan Edsbäcker,Paul Andersson,C. Lindberg,Jennifer R. Paulson,Åke Ryrfeldt,A Thalén
标识
DOI:10.1016/s0090-9556(25)06716-9
摘要
The metabolism of budesonide, (22RS)-16 alpha, 17 alpha-butylidenedioxy-11 beta,21-dihydroxypregna-1,4-diene- 3,20-dione, was studied in the 9000g supernatant fraction of livers from rat, mouse, and man. The two budesonide C-22 epimers produced different metabolites. This was explained by substrate-selective oxidation of the nonsymmetric 16 alpha, 17 alpha-acetal substituent. Epimer 22R gave 16 alpha-hydroxyprednisolone, while epimer 22S produced a metabolite tentatively identified as 23-hydroxybudesonide. Otherwise, budesonide followed the general metabolic pathways reported for synthetic glucocorticoids. Thus, oxidative metabolism predominated, 6 beta-hydroxybudesonide and delta 6-budesonide being identified in all investigated species. Reductive metabolism, giving 4,5 beta-dihydrobudesonide and 3,4,5 beta-tetrahydrobudesonide, was most pronounced in the rat. Rates and routes of budesonide metabolism were most similar in mouse and human livers. This implies that the mouse is a more relevant species than the rat in studies of the pharmacology and toxicology of budesonide.
科研通智能强力驱动
Strongly Powered by AbleSci AI